Incyte (INCY) Change in Receivables (2010 - 2026)
Incyte (INCY) reported Change in Receivables of $27.0 million for Q1 2026, up 187.31% on a YoY basis from $9.4 million in Q1 2025, and down 78.97% quarter-over-quarter from $128.5 million in Q4 2025.
Incyte (INCY) Change in Receivables (2010 - 2026) Analysis & Trends
Incyte has reported Change in Receivables for 17 years, with the latest figure at $27.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 187.31% year-over-year to $27.0 million; the trailing twelve-month figure through Mar 2026 stood at $228.8 million (up 190.81% YoY), and the FY2025 full-year result was $170.8 million, up 53.04% from the prior year.
- Change in Receivables for Q1 2026 stood at $27.0 million, down from $128.5 million in the prior quarter.
- The five-year high for Change in Receivables was $128.5 million in Q4 2025, with the low at -$64.8 million in Q3 2022.
- Historically, Change in Receivables has averaged $25.7 million across 5 years, with a median of $19.4 million in 2024.
- The largest YoY upside for Change in Receivables was 412.37% in 2025 against a maximum downside of 1672.12% in 2025.
- Incyte's Change in Receivables stood at $26.7 million in 2022, then jumped by 223.31% to $86.3 million in 2023, then gained by 12.05% to $96.7 million in 2024, then jumped by 32.89% to $128.5 million in 2025, then plunged by 78.97% to $27.0 million in 2026.
- The last three Change in Receivables figures came in at $27.0 million (Q1 2026), $128.5 million (Q4 2025), and $53.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 27.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.03 Mn |
| Mar 31, 2026 | 27.03 Mn |
| Dec 31, 2025 | 128.50 Mn |
| Dec 31, 2025 | 128.50 Mn |
| Sep 30, 2025 | 53.00 Mn |
| Sep 30, 2025 | 53.00 Mn |
| Jun 30, 2025 | 20.23 Mn |
| Jun 30, 2025 | 20.23 Mn |
| Mar 31, 2025 | -30.96 Mn |
| Mar 31, 2025 | -30.96 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 19.40 Mn |
| Sep 30, 2024 | 19.40 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Mar 31, 2024 | 1.97 Mn |
| Mar 31, 2024 | 1.97 Mn |
| Dec 31, 2023 | 86.29 Mn |
| Dec 31, 2023 | 86.29 Mn |